Overview

VIGABatrin in Post-anoxic STATus Epilepticus - Phase IIa

Status:
Not yet recruiting

Trial end date:
2022-12-31

Target enrollment:
0

Participant gender:
All

Summary

This is a pilot trial of a single loading dose of vigabatrin in post-anoxic status epilepticus.

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

University of Florida

Collaborators:

Thomas Jefferson University
Yale University

Treatments:

Vigabatrin

Criteria

Inclusion Criteria:

- age ≥ 18 years

- non-traumatic cardiac arrest (regardless of non-perfusing rhythm, etiology, or
location of arrest) in whom the decision to employ targeted temperature monitoring and
to treat unequivocal electrographic status epilepticus (as defined by the American
Clinical Neurophysiology Society: having generalized spike/sharp-wave discharges ≥ 3Hz
or any evolving pattern reaching > 4Hz, lasting ≥ 10 minutes, or comprising > 50% of
any hour of recording) has been made

- requiring anesthetic infusion for any reason,

- established enteral access within 48h of post-anoxic status epilepticus onset.

Exclusion Criteria:

- prior history of generalized epilepsy

- status epilepticus onset preceding initiation of electroencephalography monitoring